Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View
by Zacks Equity Research
Valeant (VRX) announced disappointing results in the fourth quarter. The outlook for 2018 was dismal too, which disappointed investors.
Pacira (PCRX) Posts Earnings in Q4, Revenues in Line
by Zacks Equity Research
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.
Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down
by Zacks Equity Research
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.
Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform
by Zacks Equity Research
Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer
by Arpita Dutt
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Medicines Company to Sell Infectious Disease Unit to Melinta
by Zacks Equity Research
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?
by Zacks Equity Research
GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
by Zacks Equity Research
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%
by Zacks Equity Research
Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA
by Zacks Equity Research
Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
by Zacks Equity Research
AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.
Biogen Acquires Worldwide License for Alkermes' MS Candidate
by Zacks Equity Research
Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.
AstraZeneca Files for Label Expansion of Tagrisso in Japan
by Zacks Equity Research
AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse
by Zacks Equity Research
Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.
Spectrum Doubles in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx
by Zacks Equity Research
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.